All Articles

South Korean startup VCAT AI launches a platform aggregating 30+ AI models, promising streamlined workflows, cost savings, and brand consistency for visual content creation.

Chicago’s iconic holiday kickoff returns with dazzling lights & a booming economic impact, but faces increased competition & a changing retail landscape. How is the festival adapting?

Abra Group’s agreement to incorporate SKY Airline signals a new phase of consolidation in Latin America’s aviation sector. The move aims to strengthen competition against market leader LATAM, but a unique branding strategy will be key to success.

As Vancouver accommodation costs skyrocket ahead of the 2026 FIFA World Cup, Calgary is positioning itself as a more affordable haven for fans – but questions linger over accreditation and short-term rental regulations.

For nearly three decades, Homestyle Direct has been quietly building a solution to a critical healthcare challenge: ensuring seniors have access to nutritious meals tailored to their needs. Now, as 'food as medicine' gains momentum, the company is poised for growth.

As Jamaica and other Caribbean nations grapple with the aftermath of Hurricane Melissa, Canada is stepping up aid, highlighting the growing need for climate resilience in vulnerable island states.

Onward Therapeutics’ strategic shift to Taiwan signals a broader trend: the rise of Asia as a biotech hub. The company aims to leverage Taiwan’s investment climate and talent pool to accelerate cancer therapy development.

Clinical-stage biotech Onward Therapeutics relocates HQ to Taiwan, seeking funding and a potential public listing amid a surge in the Asian nation's biotech investment and innovation. The move signals a broader trend of companies leveraging Taiwan's growing ecosystem.

As corporations increasingly explore digital asset holdings, CEA Industries is staking its future on Binance’s BNB. A deeper look at the risks, rewards, and regulatory landscape of this emerging trend.

An unprecedented partnership between Aperol and the Italian Consulate is sparking debate about the evolving role of cultural diplomacy and the growing influence of brand marketing.

A veteran of the disability insurance world is being recognized for decades of commitment to helping individuals and families secure their financial futures. Explore the growing market and the leader’s impact.

Tonix Pharmaceuticals’ FDA-approved TONMYA offers a novel approach to fibromyalgia treatment, targeting sleep disruption and offering a non-opioid alternative. Can it redefine the market?

For 12 years running, PIH Health has been recognized as a leader in digital healthcare. Explore how their commitment to innovation is reshaping patient care and cybersecurity in a rapidly evolving landscape.

Coravin’s new guide isn’t just a directory; it’s a response to evolving consumer tastes – a move towards quality, mindful consumption, and discovering hidden gems in the wine world.

Facing past financial concerns, Assembly Bio has restructured its drug pipeline, secured a significant funding injection, and now projects financial stability into late 2027, focusing on promising antiviral candidates.

Nkarta Inc. is making headway with its novel NK cell therapy for autoimmune diseases, reporting positive early data and a streamlined manufacturing process. However, the company faces growing competition in a rapidly evolving field.

Passage Bio’s PBFT02 shows promise in early trials for FTD, receiving FDA support for broader patient inclusion & securing financial stability. A deeper look at the competitive landscape & patient impact.

Orchestra BioMed is restructuring partnerships and accelerating clinical trials for its innovative bioelectronic hypertension treatment and sirolimus-eluting coronary intervention device, poised to disrupt established markets.

Biotech firm Terns Pharma is pivoting to focus solely on its lead oncology candidate, TERN-701, a novel CML treatment, after discontinuing development of its metabolic disease programs. Early data signals potential for a best-in-class therapy.

Annexon Biosciences is poised for potentially transformative milestones across its neuroinflammatory disease programs – GBS, GA, and CAD – with key regulatory filings and clinical data readouts expected over the next two years.